Evotec SE (NASDAQ: EVO) Stock Plunges Amidst Revised Guidance and Operational Challenges

• Analyst Macquarie set a price target of $2.00 for Evotec SE, indicating a potential downside of 6.54%.
• Evotec lowered its full-year guidance for 2026, citing delayed revenue from strategic partnerships and slower commercial activity.
• The biotechnology stock experienced an 11.93% drop, reaching a new 52-week low of $2.14 per share, following projections of negative adjusted Group EBITDA.

Evotec SE (NASDAQ: EVO) is a company that works with partners in the drug discovery and development industry. On July 15, 2026, an analyst from Macquarie set a price target of $2.00 for Evotec. At the time, the biotechnology stock's price was $2.14, which indicates a potential downside of 6.54% from the new target.

This cautious financial outlook follows Evotec's announcement that it is lowering its full-year guidance. As highlighted by MarketBeat, the company points to delayed revenue from strategic partnerships and slower conversion of commercial activity into sales. It also notes that timelines for new partnership agreements are longer than first expected.

Based on preliminary figures, Evotec anticipates first-half 2026 revenues of approximately €300.10 million. The company also expects a negative adjusted Group EBITDA of around €42.70 million. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a key measure of operational profitability. A negative figure indicates an operational loss for the period, impacting the company's investment analysis.

Following these results, Evotec revises its full-year 2026 guidance. The company now expects Group revenues to be between €570.00 million and €610.00 million. It also projects a negative adjusted Group EBITDA in the range of negative €70.00 million to negative €105.00 million, signaling ongoing financial challenges for the pharmaceutical industry player.

The market is reacting to this news, with Evotec's stock price falling 11.93% to $2.14 per share, a new 52-week low. As of June 30, 2026, the company's liquidity, which includes its cash and assets that can be quickly converted to cash, is expected to be around €465.60 million.